Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies Authors: Sonia Servitja, Eva Carrasco, Raquel Andrés, Álvaro Rodríguez-Lescure, Miguel Martín, Manuel Ruiz-Borrego, Ángel Guerrero, Begoña Bermejo, Antonio Antón, Montserrat Muñoz, Mireia Margeli, Isabel Álvarez, Luis Antonio Fernández, Jose Ponce, Josefina Cruz, Purificación Martínez, Sara López-Tarruella, Margarita Amenedo, Andrea Blasco, Óscar Polonio, Miguel Gil-Gil Published: 2026 ABSTRACT AbstractPurposeEndocrine therapy (ET) with or without abemaciclib/ribociclib is the current standard for intermediate- and high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients. The NATALEE trial showed that adding 3 years of ribociclib to ET improves the 4-year invasive Disease-Free Survival (iDFS) by 4.9% compared with ET alone. Real world data on long-term risk of relapse is crucial when taking decisions about the prescription of new adjuvant drugs.MethodsThis is a retrospective analysis of 8,825 HR-positive/HER2-negative EBC patients recruited from 5 adjuvant GEICAM trials enrolled from 1999 to 2010 and El Álamo IV registry (diagnosed between 2002 and 2005). To estimate their long-term outcomes, patients were grouped into 3 cohorts: cohort 1 (high-risk, stage III); cohort 2 (intermediate-risk, T0–2N1, T3N0 or T2N0 and either histological grade (G)3, or GX/G2 with Ki-67 ≥ 20%); and cohort 3 (low-risk, stage I and T2N0 and either G1, or GX/G2 with Ki-67 < 20%).ResultsThe distribution was 20.0% of patients in cohort 1, 36.0% in cohort 2 and 44.0% in cohort 3. With a median follow-up of 10.7 years, the 10-year iDFS were 53.8%, 73.8% and 84.0%, 10–y distant Disease-Free Survival were 56.3%, 77.3% and 87.8%, and 10-year overall survival (OS) were 66.7%, 84.6% and 91.9%, in cohorts 1, 2 and 3 respectively. In cohort 1, invasive relapse rate (IRR) and distant relapse rate (DDR) had a peak in years 2–3 and a second peak in year 7, while in cohorts 2 and 3 the rates increased steadily (higher at all time-points in cohort 2). In cohort 1, death rate (DR) had a soft peak in years 3–4 and years 7–8 while in cohorts 2 and 3 they increased steadily (also higher at all time-points in cohort 2).ConclusionsIntermediate-risk patients have a 10-year iDFS of 73.8%, and 10-year OS of 84.6%. The IRR, DDR and DR increased steadily in cohort 2 (as in cohort 3), in contrast to cohort 1. Further follow-up of the NATALEE trial is needed to determine the true benefit of adjuvant ribociclib in intermediate-risk patients and to decide the best ET strategy for these patients.Trial registration number ClinTrials.gov: GEICAM/9805: NCT00121992 (Study Registration Date: 2005-07-18); GEICAM/9906: NCT00129922 (Study Registration Date: 2005-08-10); GEICAM/2003-02: NCT00129389 (Study Registration Date: 2005-08-10); GEICAM/ 2003-10: NCT00129935 (Study Registration Date: 2005-08-11) and GEICAM/ 2006-10: NCT00543127 (Study Registration Date: 2007-10-11).Supplementary InformationThe online version contains supplementary material available at 10.1186/s13058-026-02300-0.Keywords: Early breast cancer, Hormone receptor (HR)-positive/HER2-negative, Risk of recurrence cohorts Introduction Adjuvant endocrine therapy (ET) reduces the risk of recurrence and death in all stages and subgroups of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC), while chemotherapy (CT) has shown a decrease in the risk of relapse in the highest risk groups [1]. However, recurrences are still common, with risk of recurrences ranging from 10 to 41% [2]. Among the relapse events, distant relapses are clearly life-threatening, and the risk of distant recurrence has been strongly correlated with tumor size and lymph node status2 (2). New therapeutic strategies, such as the combination of CDK4/6 inhibitors with ET, have recently demonstrated an improvement in clinical outcomes in patients with intermediate- and high-risk HR-positive/HER2-negative EBC [3, 4]. The monarchE trialrandomized 5,637 HR-positive/HER2-negative EBC patients with high-risk of recurrence (≥ 4 positive axillary lymph nodes or 1—3 positive nodes plus either tumor size ≥ 5 cm, or histological grade (G) 3, or Ki-67 ≥ 20%) to standard ET versus (vs.) standard ET in combination with two years of abemaciclib (150 mg twice daily). In the latest analysis reported so far, with a median follow-up of 54 months the 5-year invasive disease-free survival (iDFS) rate in the abemaciclib plus ET arm was 83.6% compared to 76.0% in the ET alone arm with an absolute improvement of 7.6% (HR: 0.680, p < 0.0001) [5]. The phase 3 multicenter, randomized, open-label NATALEE trial included 5,101 HR-positive/HER2-negative EBC patients with either intermediate-risk (stage IIA, if lymph node negative [N0] with either G3 or G2 with Ki-67 ≥ 20%, or high-risk genomic platform) or very high-risk (stage IIB or stage III) of recurrence. Patients were randomized to receive standard ET vs. standard ET in combination with three years of ribociclib (400 mg daily, 3 weeks on/one week off). In the latest update with a median follow-up of 44.2 months [6], the risk for invasive disease was reduced by 25.1% with ribociclib plus ET compared with ET alone (HR 0.715, 95% CI [0.609, 0.840]; P < 0.0001). The 4-year iDFS rate was 88.5% for the ribociclib plus ET arm compared with 83.6% for the ET alone arm, with an absolute improvement of 4.9%. Knowing the risk of recurrence and the relapse times in a real-world population of EBC treated in recent years can be of great help when interpreting the results of trials with new adjuvant drugs. Based on this we performed the current study to evaluate the outcomes of patients with HR-positive/HER2-negative EBC divided by recurrence risk cohorts. These data will allow us to correctly select the patients who will benefit most from these new adjuvant drugs. Methods This study includes data from 5 GEICAM adjuvant randomized clinical trials in EBC patients and one real world data (RWD) breast cancer (BC) registry. The adjuvant trials were the following: GEICAM/9805 [7] (docetaxel-doxorubicin-cyclophosphamide [TAC] × 6 cycles vs. fluorouracil-doxorubicin-cyclophosphamide [FAC] × 6 cycles in N0 patients); GEICAM/2003-02 [8] (FAC × 6 cycles vs. FAC × 4 cycles followed by weekly paclitaxel × 8 weeks in N0 patients); GEICAM/9906 [9] (fluorouracil/epirubicin/cyclophosphamide [FEC] × 6 cycles versus FEC × 4 cycles followed by weekly paclitaxel × 8 cycles in lymph node positive [N +] patients); and GEICAM/2003-10 [10] (epirubicin/cyclophosphamide × 4 cycles followed by docetaxel × 4 cycles versus epirubicin/docetaxel × 4 cycles followed by capecitabine × 4 cycles in N + patients). In these four trials, all subtypes were included, and women with HR-positive tumors were scheduled to receive at least 5 years of ET after the end of CT (tamoxifen or aromatase inhibitors, or a sequence of both). The last adjuvant trial was the GEICAM/2006-10 [11] in which patients with N0 and N + received anastrozole × 5 years vs. anastrozole × 5 years combined with fulvestrant for the first 3 years. These five trials included patients diagnosed from 1999 to 2010. El Álamo IV is a retrospective registry performed to characterize BC cases diagnosed in Spain between 2002 and 2005 in 43 Spanish sites. The current study was approved by an institutional review board. The data was analyzed at the Statistical Unit of GEICAM using SAS, version 9.4 (SAS Institute Inc.). Patients For this analysis we included women and men with HR-positive/HER2-negative EBC who received standard adjuvant ET that were divided into three cohorts based on their risk of recurrence. The high-risk cohort (cohort 1) included patients with stage III; the intermediate-risk cohort (cohort 2) included patients T0-2N1M0, T3N0M0 or T2N0M0 and either G3, or GX/G2 with Ki-67 ≥ 20%. The high- and intermediate-risk patients had similar characteristics to those randomized in the NATALEE trial. The low-risk cohort (cohort 3) included patients with stage I or T2N0M0 and either G1, or GX/G2 with Ki-67 < 20%. Objectives and endpoints The main objectives were to determine iDFS, Distant Disease-Free Survival (dDFS) and Overall Survival (OS) at 5 and 10 years in the 3 cohorts. iDFS was defined as time from adjuvant ET initiation to the first date of diagnosis of any of the following events: ipsilateral invasive BC relapse, distant BC relapse, contralateral invasive BC, second primary invasive cancer (non-BC) and death due to any cause. dDFS was defined as time from adjuvant ET initiation to the first date of diagnosis of any of the following events: distant BC relapse, second primary invasive cancer (non-BC) and death due to any cause. OS was defined as time from adjuvant ET initiation to the date of death from any cause. Other objectives were to determine the yearly (years 1 to 10) evaluation of Invasive Relapse Rate (yIRR), Distant Relapse Rate (yDRR) and Death Rate (yDR) in the 3 cohorts. yIRR was defined as the proportion of patients with any of the following events: ipsilateral (local/regional) invasive BC relapse or distant BC relapse per year. yDRR was defined as the proportion of patients with distant BC relapse per year (either as first or subsequent relapse if first relapse was local/regional). yDR was defined as the proportion of deaths per year. Statistical analysis The Kaplan–Meier limit-product method was used to estimate all time to event endpoints (iDFS, dDFS and OS) and the survival curves were presented graphically. Yearly times to events were reported with 95% confidence interval (CI). Cox models were used to estimate adjusted Hazard Ratios of iDFS, dDFS and OS for the intermediate- and high-risk cohorts using the low-risk group as the reference. Hazard ratios were adjusted by clinico-pathologic covariates: Age (categorized), nodal status, tumor size, histological grade, Ki-67 expression, chemotherapy exposure, ET regimen, and data source (clinical trial versus registry). The yearly relative incidence rate of events, was used to evaluate the yIRR, yDRR and yDR in years 1 to 10. All analyses were performed in the whole population and by risk of recurrence cohorts. All statistical tests used in the analysis were two-sided and calculated with a significance level of 0.05. Results Patients characteristics We selected 8,825 patients for this pooled analysis; their distribution by trial was the following: 388 from the GEICAM/9805, 674 from the GEICAM/9906, 1,099 from the GEICAM/2003-02, 952 from the GEICAM/2003-10, 749 from the GEICAM/2006-10 and 4,963 from the El Álamo IV registry (Fig. 1). The distribution according to the risk of recurrence was: 1,769 (20%), 3,179 (36%) and 3,877 (44%) patients in the high-, intermediate- and low-risk cohorts, respectively. Flowchart The distribution in the intermediate-risk cohort was: 1,093 (34.4%) T2N1M0, 1,453 (45.7%) T0-1N1M0, 161 (5.1%) T3N0M0, 384 (12.1%) T2N0M0 and G3, 16 (0.5%) T2N0M0 GX with Ki-67 ≥ 20% and 72 (2.2%) T2N0M0 and G2 with Ki-67 ≥ 20%. It is worth noting that T2N0M0 patients with both Ki-67 and unknown histological grade were excluded from the analysis. Baseline demographic and disease characteristics are described in Table 1. Median age was 55 years; mostly female (99.5%), from which 36.3% were premenopausal, 62.2% were postmenopausal and 1.5% unknown; 82.5% had invasive ductal carcinoma, 23.6% G3 tumors and 31.4% had tumors with Ki-67 ≥ 20% (information not available in 31.4% of patients). Prior chemotherapy in the neo/adjuvant setting was used in 75.5% of patients (88.8%, 88.1% and 59.1% in the high-, intermediate- and low-risk cohorts, respectively). Anthracycline-based CT was the most used regimen in 94.2% of patients (96.3%, 96.2% and 90.3% in cohorts 1, 2 and 3, respectively). The median exposure time to adjuvant ET was 5 years (range: 0.–15 years), similar across all cohorts. SERMs were administered, either alone, in sequence or in combination with aromatase inhibitors in 67.4% of patients. Aromatase inhibitors were administered, either alone, in combination or in sequence in 63.7% of patients. Table 1Baseline Characteristics of patientsHigh-riskIntermediate-riskLow-riskTotal1,769 (20.0%)3,179 (36.0%)3,877 (44.0%)N = 8,825Median age, years (range)55 (24–90)54 (23–89)56 (19–90)55 (19–90)Sex, n (%)Female1,757 (99.3%)3,167 (99.6%)3,859 (99.5%)8,783 (99.5%)Male12 (0.7%)12 (0.4%)18 (0.5%)42 (0.5%)Menopausal status, n (%)Postmenopausal1,075 (60.8%)1,871 (58.8%)2,516 (64.9%)5,462 (61.9%)Premenopausal651 (37.8%)1,241 (39.0%)1,295 (33.4%)3,187 (36.1%)Not available31 (1.8%)55 (1.7%)48 (1.2%)134 (1.5%)Not applicable12 (0.7%)12 (0.4%)18 (0.5%)42 (0.5%)Tumor size, n (%)T1466 (26.3%)1,452 (45.7%)3,334 (86.0%)5,252 (59.5%)T2721 (40.8%)1,564 (49.2%)542 (14.0%)2,827 (32.0%)T3300 (17.0%)161 (5.0%)0461 (5.2%)T4257 (14.5%)00257 (2.9%)TX*25 (0.01%)2 (0.0%)128 (0.0%)Lymph node statusN090 (5.1%)633 (19.9%)3,877 (100%)4,600 (52.1%)N + 1,679 (94.9%)2,546 (80.1%)04,225 (47.9%)Histological tumor type, n (%)Invasive Ductal Carcinoma1,390 (78.6%)2,680 (84.3%)3,214 (82.9%)7,284 (82.5%)Invasive Lobular Carcinoma289 (16.3%)325 (10.2%)399 (10.3%)1,013 (11.5%)Other90 (5.1%)174 (5.5%)264 (6.8%)528 (6.0%)Histological tumor grade, n (%)G1, well differentiated226 (12.8%)550 (17.3%)1,070 (27.6%)1,846 (20.9%)G2, moderately differentiated776 (43.9%)1,356 (42.7%)1,782 (46.0%)3,914 (44.3%)G3, poorly differentiated485 (27.4%)972 (30.6%)625 (16.1%)2,082 (23.6%)GX, unknown/Missing282 (15.9%)301 (9.5%)400 (10.3%)983 (11.1%)Ki-67 expression, n (%)< 20%557 (31.5%)937 (29.5%)1,792 (46.2%)3,286 (37.2%)≥ 20%587 (33.2%)976 (30.7%)1,207 (31.1%)2,770 (31.4%)Unknown625 (35.3%)1,266 (39.8%)878 (22.6%)2,769 (31.4%)Breast Surgery, n (%)Conservative595 (33.6%)1,810 (56.9%)2,836 (73.1%)5,241 (59.4%)Mastectomy1,159 (65.5%)1,357 (42.7%)1,012 (26.1%)3,528 (40.0%)Not specified15 (0.8%)12 (0.4%)29 (0.7%)56 (0.6%)Prior Chemotherapy, n (%)No198 (11.2%)377 (11.9%)1,587 (40.9%)2,162 (24.5%)Yes1,571 (88.8%)2,802 (88.1%)2,290 (59.1%)6,663 (75.5%)Type of Chemotherapy, n (%)(1)Anthracyclines607 (38.6%)1,368 (48.8%)1,518 (66.3%)3,493 (52.4%)Anthracyclines + Taxanes907 (57.7%)1,327 (47.4%)549 (24.0%)2,783 (41.8%)CMF28 (1.8%)54 (1.9%)196 (8.6%)278 (4.2%)Taxanes22 (1.4%)45 (1.6%)14 (0.6%)81 (1.2%)Other CT7 (0.4%)8 (0.3%)13 (0.6%)28 (0.4%)Median duration of adjuvant ET, years (range)5 (0–12)5 (0–14)5 (0–15)5 (0–15)Duration of ET, years≤ 5778 (60.5%)1,209 (55.5%)1,480 (53.4%)3,467 (55.6%)> 5 and ≤ 7400 (31.1%)821 (37.7%)1,129 (40.7%)2,350 (37.7%)> 7107 (8.3%)148 (6.8%)163 (5.9%)418 (6.7%)Type of adjuvant ET, n (%)(2)SERM651 (36.9%)1,150 (36.2%)1,378 (35.5%)3,179 (36.1%)SERM + Aromatase Inhibitors532 (30.2%)972 (30.6%)1,256 (32.4%)2,760 (31.3%)Aromatase Inhibitors505 (28.6%)881 (27.7%)1,112 (28.7%)2,498 (28.3%)Aromatase inhibitors + SERD74 (4.2%)167 (5.3%)123 (3.2%)364 (4.1%)LHRH analogs(3)1 (0.1%)4 (0.1%)7 (0.2%)12 (0.1%)Other ET01 (0.0%)1 (0.0%)2 (0.0%)SERD1 (0.1%)1 (0.0%)02 (0.0%)*Patients with TX at high-risk category is known to be stage III, patients with TX at intermediate-risk category is known to be stage II and patients with TX at low-risk category is known to be stage I(1) Percentages calculated considering only patients treated with prior CT(2) ET was unknown in 5 patients from Cohort 1 and 3 from Cohort 2(3) LHRH analogues were administered to 8.3% of premenopausal patients (5% in combination with SERMs, 2.4% in combination with SERMs and aromatase inhibitors [combined or in sequence], 0.5% in combination with aromatase inhibitors and 0.3% alone)CMF denotes cyclophosphamide, methotrexate and 5-fluorouracil; CT denotes chemotherapy; ET denotes endocrine therapy; G denotes grade; LHRH denotes Luteinizing Hormone-Releasing Hormone; SERD denotes Selective Estrogen Receptor Degrader; SERM denotes Selective Estrogen Receptor Modulator Baseline Characteristics of patients *Patients with TX at high-risk category is known to be stage III, patients with TX at intermediate-risk category is known to be stage II and patients with TX at low-risk category is known to be stage I (1) Percentages calculated considering only patients treated with prior CT (2) ET was unknown in 5 patients from Cohort 1 and 3 from Cohort 2 (3) LHRH analogues were administered to 8.3% of premenopausal patients (5% in combination with SERMs, 2.4% in combination with SERMs and aromatase inhibitors [combined or in sequence], 0.5% in combination with aromatase inhibitors and 0.3% alone) CMF denotes cyclophosphamide, methotrexate and 5-fluorouracil; CT denotes chemotherapy; ET denotes endocrine therapy; G denotes grade; LHRH denotes Luteinizing Hormone-Releasing Hormone; SERD denotes Selective Estrogen Receptor Degrader; SERM denotes Selective Estrogen Receptor Modulator Outcomes With a median follow-up time of 10.7 years (range 0.0–18.1 years), the 5 and 10 years iDFS rates for the overall population were 87.9% and 74.3%, respectively, see Fig. 2A and supplementary Table 1 (for information about specific events). For the high-, intermediate- and low-risk patients, iDFS rates at 5 years were 73.4%, 87.9% and 94.6%, respectively; the respective figures at 10 years were 53.8%, 73.8% and 84.0% (Fig. 2B). Invasive Disease-free Survival (iDFS) from the start of adjuvant ET. A. Overall population; B. By risk of recurrence cohorts; C. By risk of recurrence cohorts and lymph node subgroups The adjusted Cox model Hazard Ratios for iDFS (Supplementary Table 2) resulted in a significant increase of risk of recurrence for patients in the intermediate-risk and high-risk cohorts compared to the low-risk group (Hazard Ratio of 1.6 [95% CI: 1.4–1.8] and 2.6 [95% CI: 2.2–3.1] for the intermediate- and high-risk group, respectively). With respect to dDFS, the rates at 5 and 10 years for the overall population were 89.5% and 77.7% (Fig. 3A and supplementary Table 1). dDFS rates at 5 years for the high-, intermediate- and low-risk patients were 75.4%, 89.8% and 95.6%, respectively; the respective figures at 10 years were 56.3%, 77.3% and 87.8% (Fig. 3C). Distant Disease-free Survival (dDFS) and Overall Survival (OS) from the start of adjuvant ET. A. dDFS overall population; B. OS overall population; C. dDFS by risk of recurrence cohorts; D. OS by risk of recurrence cohorts; E. dDFS by risk of recurrence cohorts and lymph node subgroups; F. OS by risk of recurrence cohorst and lymph node subgroups The adjusted Cox model Hazard Ratios for dDFS (Supplementary Table 2) resulted in a significant increase of risk of recurrence for patients in the intermediate-risk and high-risk cohorts compared to the low-risk group (Hazard Ratio of 1.9 [95% CI: 1.6–2.2] and 3.3 [95% CI: 2.8–3.9] for the intermediate- and high-risk group, respectively). The OS rates for the overall population at 5 and 10 years were 94.0% and 84.2%, respectively (Fig. 3B). For the high-, intermediate- and low-risk patients, OS rates at 5 years were 85.4%, 94.8% and 97.3%, respectively; the respective figures at 10 years were 66.7%, 84.6% and 91.9% (Fig. 3D). The adjusted Cox model Hazard Ratios for OS (Supplementary Table 2) resulted in a significant increase of risk of recurrence for patients in the intermediate-risk and high-risk cohorts compared to the low-risk group (Hazard Ratio of 2.1 [95% CI: 1.7–2.5] and 3.8 [95% CI: 3.1–4.6] for the intermediate- and high-risk group, respectively). We performed subgroup analyses by lymph node status (N0 and N +) in the high- and intermediate cohorts. For high-risk patients iDFS rates at 5 years were 76.5% for N0 and 73.2% for N + and iDFS at 10 years were 58.3% for N0 and 53.5% for N + . In intermediate-risk patients iDFS rates at 5 years were 86.1% for N0 and 88.3% for N + and iDFS at 10 years were 72.8% for N0 and 74.1% for N + (Fig. 2C). For high-risk patients dDFS rates at 5 years were 78.8% for N0 and 75.2% for N + and dDFS at 10 years were 60.6% for N0 and 56.0% for N + . In intermediate-risk patients dDFS rates at 5 years were 88.2% for N0 and 90.2% for N + and dDFS at 10 years were 76.4% for N0 and 77.5% for N + (Fig. 3E). For high-risk patients OS rates at 5 years were 89.9% for N0 and 85.2% for N + and OS at 10 years were 72.1% for N0 and 66.4% for N + . In intermediate-risk patients OS rates at 5 years were 94.3% for N0 and 94.9% for N + and OS at 10 years were 82.0% for N0 and 85.3% for N + (Fig. 3F). The yIRR, yDRR and yDR in years 1 to 10 for the overall population are shown in supplementary Table 3 and represented graphically in Fig. 4. yIRR and yDRR increased from year 2 till year 3 followed by a second peak at years 7–8; yDR increased steadily from year 1 to 10. Yearly Invasive Recurrence rate (yIRR), Yearly Distant Recurrence Rate (yDRR) and Yearly Death Rate (yDR) in years 1 to 10. A. yIRR in years 1 to 10; B. yDRR in years 1 to 10; C. yDR in years 1 to 10 In high-risk patients yIRR and yDRR had a peak in years 2–3 and a second peak in years 7–8, while in intermediate- and low-risk patients the rates increased steadily from year 1 to 10 (being higher at all time-points in intermediate-risk patients). In high-risk patients, yDR had a soft peak from year 3 till year 4 followed by a second peak at years 7–8 while in intermediate- and low-risk patients they increased steadily from year 1 to 10 (being also higher at all time-points in intermediate-risk patients). Discussion Patients with HR-positive/HER2-negative EBC are at risk for recurrence up to 20 years after initial diagnosis, with more than half of these recurrences occurring beyond 5 years from diagnosis [2, 12]. This study presents the results of long-term follow-up of patients included in the GEICAM database who participated in prospective clinical trials between 1990 and 2010 or from El Álamo IV, a RWD BC registry. Patients were divided into three levels of risk of relapse, and the interval between diagnosis and date of relapse and/or death was analyzed. Following the positive results of the monarchE and NATALEE trials, interest is rising in identifying patients at high or intermediate risk of relapse who may benefit from adjuvant treatment with abemaciclib for two years or ribociclib for three years. It is important to accurately assess the risk of relapse in individual patients, especially when considering the 20% treatment discontinuation rate caused by cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) toxicity in both trials. Additionally, the high cost of these treatments must be considered in these common clinical scenarios. The definition of high- intermediate- and low-risk of recurrence in HR-positive/HER2-negative EBC is relatively imprecise and is conditioned by traditional anatomical criteria (TNM) and by biological factors such histological grade, proliferation index (Ki-67) or genomic platforms. Patients in our study were divided into 3 cohorts according to those recurrence risk parameters: Cohort 1 (high-risk: stage III), Cohort 2 (intermediate-risk: T2N1, T0N1, T1N1, T3N0 or T2N0 plus either histological Grade (G)3, or GX/G2 with Ki-67 ≥ 20%) and Cohort 3 (low-risk: stage I and T2N0 plus either G1, or GX/G2 with Ki-67 < 20%). Other investigators have also examined patients’ outcomes based on anatomical criteria. For instance, Pan et al. conducted an analysis involving 74,194 women with HR-positive BC with T1 or T2 tumors who were enrolled in 78 trials and were scheduled to receive 5 years of ET. Patients were categorized into three cohorts according to their pathological nodal status at diagnosis: N4-9, N1-3 or N0, representing 17%, 43% and 40% of the analyzed patients, respectively [2]. Recently, Arecco et al.published data from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomized clinical trials exploring patients’ prognosis of different cohorts based on the inclusion criteria of monarchE and NATALEE trials [13]. This research compares the risk definitions used in both trials and evaluates disease-free survival (DFS) and OS outcomes. The analysis included 4,795 patients with EBC; 28% were classified as high-risk by the monarchE criteria, while 56% met the NATALEE criteria which encompasses both high- and intermediate-risk patients. Another recent publication on this topic is the Netherlands cohort. It classifies patients with HR + /HER2- BC according to nodal status, tumor size, and histological grade, using monarchE criteria to select high-risk patients, and the Dutch guideline to categorize all other patients as low- or intermediate-risk. Among 87,455 patients analyzed from 2011 to 2019, 13% were classified as high-risk [14]. In our study, the distribution of patients was 20% in the high-risk cohort, 36% in the intermediate-risk group, and 44% in the low-risk group. As can be seen, the distribution of patients does not match between the studies, since the criteria used to define the risk of relapse are not consistent across them. Identifying patients with minimal risk of metastasis is crucial. In our cohort, low-risk patients had iDFS rates of 94.6% at 5 years and 84% at 10 years; dDFS rates were 95.6% at 5 years and 87.8% at 10 years. Pan et al. found the at 5- and 10-year distant recurrence risks in the N0 cohort to be 6% and 11%, respectively [2]. These findings align with our data in the low-risk cohort. These favorable outcomes suggest that most low-risk patients may not need to endure the side effects and costs of CDK4/6 inhibitors for 2 to 3 years if their metastasis risk is very low. Our study also found that intermediate-risk patients had 5- and 10-year iDFS rates of 87.9% and 73.8%; 5- and 10-year dDFS rates of 89.8% and 77.3% and 5- and 10-year OS rates of 94.8% and 84.6%. Importantly, approximately 23% of patients had a dDFS event at 10 years. Pan et al.’s analysis showed a 10% and 19% risk of distant recurrence at 5 and 10 years in the N1-3 cohort [2]. The results are quite similar to those observed in our intermediate-risk cohort even though the populations are not completely comparable in terms of clinico-pathological characteristics since our intermediate-risk group also included N0 patients with T3 tumors, or T2 tumors with G3, or GX/G2 with Ki-67 ≥ 20%. Arecco et al. published DFS data at 3 and 7 years, the 3-year DFS was 93% for high-risk stage II patients, and 7-year DFS was 89% in concordant low risk criteria [13], also within the range of our study. One could point out that all our patients received treatment over a decade ago, so current treatment strategies may now differ. However, it is worth noting that 40% of our patients received > 5 years of ET, reflecting an early adoption of extended treatment that bridges the gap between historical and current standards. These figures are significant enough to justify new treatment strategies for these patients, such as the use of CDK4/6i. NATALEE reported a 4-year iDFS rate of 89.6% in stage II patients in the control arm [6], similar to what we observed in our intermediate-risk patient cohort with an iDFS rate of 90.4% at 4 years. With the addition of ribociclib, the 4-year iDFS was improved by 4.3%. At this point, further follow-up of the NATALEE trial is needed to see the real potential benefit of adjuvant ribociclib in this population at 5 and 10 years. Furthermore, it is quite noteworthy the interval-to-relapse and death curves showing that yIRR, yDRR and yDR increased steadily in both low- and intermediate-risk patients. In contrast, in high-risk patients, yIRR and yDRR peaked in years 2–3 and again in year 7, possibly due to the end of ET at 5 years. It will be interesting to determine whether CDK4/6i (abemaciclib o ribociclib) can reduce the peak of recurrence at 2–3 years in high-risk patients. The duration of adjuvant CDK4/6i may be crucial in reducing this early peak of recurrence. For the 7-year peak, extending ET beyond 5 years could be an option, although the use of CDK4/6i may also affect the long-term outcomes of these patients, by influencing this second peak of recurrence. Longer follow-up of the monarchE and NATALEE trials will clarify if 2 or 3 years of CDK4/6i can reduce both early and late peaks of recurrence. It will be more difficult to identify the best adjuvant ET strategy for intermediate-risk patients in which we observe a steady increase of recurrences from year 1 to 10; different adjuvant strategies may be needed for these patients. New oral SERDs, currently under study in the adjuvant setting for patients at intermediate- and high-risk of relapse [15–18] might be more effective than aromatase inhibitors. Additionally, their more favorable toxicity profile compared with CDK4/6i could allow extension of ET beyond 5 years to control this ongoing risk of recurrence. A key strength of our study is its reliance on RWD from the El Álamo IV registry and GEICAM randomized clinical trials with long follow-up. As a limitation, the ET used in our study may differ from that currently used for intermediate- and high-risk patients in routine clinical practice. Specifically, the use of aromatase inhibitors (received only by 63.7% of patients) and ovarian suppression which was used in only 8.3% of premenopausal patients, differs from current practice following the results of the SOFT and TEXT trials [19, 20]. However, the fact that our iDFS outcomes are highly comparable to those of the control arms of contemporary trials such as NATALEE, suggests that the impact of this 'era effect' on overall risk patterns is limited. This observation highlights that patients with intermediate- and high-risk HR + /HER2- BC maintains a significant residual risk regardless of the ET backbone used, reinforcing the rationale for extending ET or adding novel agents in the adjuvant setting [21]. Additionally, the lack of genomic data and limitations in local Ki-67 assessment restrict our ability to better adjust the risk of recurrence. In conclusion, these long-term data from GEICAM adjuvant trials and the El Álamo IV registry demonstrate that patients with intermediate-risk HR + /HER2- BC face a significant residual risk of recurrence, with a 10-year iDFS of 73.8%, a 10-year dDFS of 77.3%, and a 10-year OS of 84.6%. These findings provide a robust clinical rationale for current treatment intensification strategies in this population. Specifically, the persistent risk observed—with more than half of recurrences occurring after the fifth year—supports the potential benefit of incorporating novel agents such as CDK4/6 inhibitors (e.g., ribociclib) into the adjuvant ET backbone. While longer follow-up from the NATALEE trial is essential to confirm the long-term impact of these therapies, our data underscore the importance of tailoring adjuvant strategies to the sustained risk profile of each patient. Ultimately, these historical outcomes provide a contextual benchmark that highlights the window of opportunity for therapeutic escalation in intermediate-risk disease. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We acknowledge the patients included in the analysis and their families and all the participating investigators. We also acknowledge the support of the GEICAM staff. Author contributions S. Servitja, M. Gil-Gil and E. Carrasco conceived the study design. S. Servitja, M. Gil, R. Andrés, A. Rodríguez-Lescure, M. Martín, M. Ruiz, A. Guerrero, B. Bermejo, A. Antón, M. Muñoz, I. Álvarez, L.A. Fernández, J. Cruz, P. Martínez, S. López-Tarruella, M. Margeli, J. Ponce and M. Amenedo contributed to data collection. S. Servitja, M. Gil and E. Carrasco interpreted the results. A. Blasco analyzed the data. S. Servitja, M. Gil, E. Carrasco and O. Polonio contributed to manuscript preparation. All authors contributed to the reviewing of the manuscript and approved the final version. S. Servitja and M. Gil had full access to all the data from the study and had final responsibility for the decision to submit for publication. Funding This work was supported by Novartis, S.A., which not participated in data collection, analysis, interpretation of the data, writing the report or decision to submit the paper for publication. The trial sponsor is GEICAM Spanish Breast Cancer Group. The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The content is solely the responsibility of the authors. Data availability The studies from which the patients were selected were completed and closed, except *Alamo IV* registry which is in data cleaning process. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Conflict of interests Dr. Sonia Servitja has received speaker honoraria by Daiichi-Sankyo, AstraZeneca, Roche Pharma and Novartis and advisory by Seagen, Genomic Health, MSD and Daiichi-Sankyo. Dr. Eva Carrasco has stock and other ownership interests from Lilly, has received travel and accommodations support from Roche and her husband has participated in consulting and advisory board activities with Bristol-Myers Squibb, Novartis, Celgene, Roche Pharma, Janssen, Amgen, Incyte, Abbvie and Pfizer, has received travel and accommodations support from Celgene, Novartis and Bristol-Myers Squibb. His institution has received research funding from Celgene, Janssen, Bristol-Myers Squibb, Novartis, Celgene, Roche/Genentech, Amgen, Pfizer and Abbvie. GEICAM has received research funding from Roche/Genentech, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Merck Sharp & Dohme, Pierre Fabre and Takeda. Dr. Alvaro Rodríguez-Lescure has received speaker honoraria by Pfizer, Novartis, AstraZeneca, Daichii-Sankyo and Seagen and advisory by Pfizer, Novartis, Roche, AstraZeneca, Daiichi-Sankyo, Pierre Fabre and Seagen. Dr. Miguel Martín has received consulting fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology and Pfizer; speakers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis, Daiichi Sankyo, and Pfizer; and contracted research fees from Roche, Novartis, and PUMA. Dr. Angel Guerrero has received institutional grant by Pfizer, advisory by Novartis, Palex, Pfizer, AstraZeneca, Pierre Fabre, travel grant by Roche Pharma, Pfizer and Novartis and speaker honoraria by Novartis, Pfizer, Lilly, Pfizer, AstraZeneca. Dr. Antonio Antón has received speaker honoraria by Astrazeneca-Daiichi-Sankyo, Eli Lilly and Seagen, advisory by AstraZeneca-Daichii-Sankyo, Eli Lilly, Gilead and personal grant by AstraZeneca-Daiichi-Sankyo, Eli Lilly, Gilead, Pfizer and Seagen. Dr. Isabel Álvarez has received speaker honoraria by Roche Pharma, advisory by AstraZeneca, Pfizer, Novartis, Roche Pharma and Gilead and research funding by AstraZeneca, Pfizer, Novartis and Roche PharmaDr. Josefina Cruz has received speaker honoraria by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Pierre Fabre, Eisai, Lilly, Daiichi Sankyo, Seagen, Gilead and Pfizer and advisory by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Eisai, Lilly, GlaxoSmithKline, Pfizer, Gilead, Seagen and Daiichi Sankyo. Dr. Sara López-Tarruella has received speaker honoraria by Lilly and consulting or advisory role by AstraZeneca, Novartis, Roche Pharma, Pfizer, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo Europe GmbH, Gilead Sciences, MSD, GlaxoSmithKline, Veracyte. Dr. Margarita Amenedo has received honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events by Astrazeneca, Merk and Pharma Mar and support for attending meetings and/or travel by Astrazeneca, Merk, Lilly, Incyte and GSK and Dr. Miguel Gil has received honoraria by Pfizer, Astrazeneca-Daiichi-Sankyo and Gilead, consulting or advisory role by Seagen, Astrazeneca-Daiichi-Sankyo and Astrazeneca and travel/ accomodations by Novartis, Roche and Pfizer. The rest of the authors have no conflicts of interest. GEICAM has received research funding from Novartis, S.A. Ethical approval The study protocol of the original clinical trials and of the BC registry were approved by an institutional review board and the national regulatory agency. Informed consent was obtained from all individual participants included in the clinical trials. In the BC registry it was not necessary to obtain the informed consent because the national regulatory agency classified it as an observational study not post-authorization, not needing consent, as data were extracted from the patient’s history without interviewing them. The current study was approved by an institutional review board. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The studies from which the patients were selected were completed and closed, except *Alamo IV* registry which is in data cleaning process. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.